HOS 2021: 9th International Symposium
RedShiftBio will be showcasing the superior benefits of Microfluidic Modulation Spectroscopy (MMS) - powered AQS3™pro for protein secondary structure analysis at the HOS 2021 Virtual Symposium. MMS can help to quickly identify better biotherapeutic formulations, promptly and easily eliminate high risk drug candidates, and determine structure-function relationship and detect failures using high sensitivity measurements. Moreover, with AQS3™pro MMS can reduce reliance on clinical and animal studies ― significantly cutting time and costs to market.
Protein higher order structure (HOS) includes the analysis of the secondary structure of a protein. Changes in the HOS of proteins can contribute to product quality, and potentially safety, efficacy, and pharmacokinetic properties of protein therapeutics. Regulatory agencies demand assessment of HOS to determine how protein structure is affected by manufacturing, storage and delivery. This Symposium will address various biophysical methods for assessment of protein HOS, as well as the applications of the appropriate tools during the different stages of protein therapeutic development and biosimilarity assessments, the theory and practice of biophysics, technical data from academia and industry as well as method qualification, validation and setting specifications.
Join us for our scheduled presentations:
Monday, April 12 at 9:10 AM EST: RedShift's Matt McGann will showcase the superior benefits of Microfluidic Modulation Spectroscopy (MMS).
Thursday, April 15 starting at 8 AM EST: RedShift's Dr. Patrick King presents our poster on long-term protein stability prediction using 'micro' changes in secondary structure measured by Microfluidic Modulated Spectroscopy.
Want to view the poster presenation?
Enter your details and we'll email it to you after the event.